The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow‐up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation

The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study showed that 40 mg Olmesartan medoxomil (OM) versus placebo delayed microalbuminuria onset in patients with type 2 diabetes and normoalbuminuria.

Saved in:

Bibliographic Details
Main Authors:	Menne, Jan (Author) , Ritz, Eberhard (Author) , Ruilope, Luis M. (Author) , Chatzikyrkou, Christos (Author) , Viberti, Giancarlo (Author) , Haller, Hermann (Author)
Format:	Article (Journal)
Language:	English
Published:	25 Apr 2014
In:	Journal of the American Heart Association Year: 2014, Volume: 3, Issue: 2
ISSN:	2047-9980
DOI:	10.1161/JAHA.114.000810
Online Access:	Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1161/JAHA.114.000810 Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/JAHA.114.000810
Author Notes:	Jan Menne, Eberhard Ritz, Luis M. Ruilope, Christos Chatzikyrkou, Giancarlo Viberti, Hermann Haller

Description
Summary:	The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study showed that 40 mg Olmesartan medoxomil (OM) versus placebo delayed microalbuminuria onset in patients with type 2 diabetes and normoalbuminuria.
Item Description:	Gesehen am 22.09.2020
Physical Description:	Online Resource
ISSN:	2047-9980
DOI:	10.1161/JAHA.114.000810